Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$72.35 - $88.99 $144,700 - $177,980
2,000 Added 47.62%
6,200 $465,000
Q4 2023

Feb 13, 2024

BUY
$42.42 - $80.28 $178,164 - $337,176
4,200 New
4,200 $309,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.02B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Omers Administration Corp Portfolio

Follow Omers Administration Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Omers Administration Corp, based on Form 13F filings with the SEC.

News

Stay updated on Omers Administration Corp with notifications on news.